Over the past year a number of new antifungal agents have been evaluated for use in superficial and deep mycoses. The four main drugs that have dominated the antifungal literature are amorolfine, a topical agent that seems to be effective in vaginal candidiasis and dermatophytosis, terbinafine, which is used mainly in the treatment of dermatophyte infections, and fluconazole and itraconazole, used particularly as empiric treatment in immunosuppressed patients. These studies have been reported and as a consequence the dominant published articles are clinical trials and animal and pharmacokinetic studies. This review introduces the reader to some new developments in antifungal medications in skin and nail mycosis and in empiric therapy in neutropenic patients, emphasizing the diagnostic procedures of superficial and deep fungal infections.